Media Coverage

Suhash Harwani, Ph.D, Senior Director of Science & Technology for Employer Solutions at Quest Diagnostics, shares drug positivity and testing options that employers should know about.

On Jan. 31, Fortune released its World's Most Admired Companies list, which included healthcare companies. The list, a partnership between Fortune and global management consulting firm Korn Ferry, follows an examination of about 1,500 candidates: the 1,000 largest U.S. companies ranked by revenue, along with non-U.S. companies in Fortune's Global 500 database that have revenues of $10 billion or more.

Just as users around the world are surely strapping on new Fitbits with an aim of tackling health-focused New Year’s resolutions, so too is Fitbit itself kicking off 2024 with its sights set on a new goal. The Google-owned fitness tracker maker is teaming up with Quest Diagnostics, according to a Wednesday release, to study how the combination of the two companies’ products could potentially help improve metabolic health, which is linked to conditions like diabetes, heart disease and stroke.

Quest Diagnostics has acquired select assets of outreach laboratory services in Pennsylvania and Ohio from Steward Health Care System, a large, private, and fully-integrated for-profit system based in Dallas. In addition, subject to transfer of the laboratory license, Quest has also acquired certain assets from the laboratory business serving Hawthorn Medical Associates in Dartmouth, MA.

Haystack Oncology said on Monday that it has struck a deal to investigate the use of its minimal residual disease (MRD) testing technology in non-small cell lung cancer (NSCLC) in collaboration with research organization Alliance Foundation Trials (AFT).

Quest Diagnostics and Scipher Medicine announced a collaboration designed to expand patient access to diagnostic services for rheumatoid arthritis. Under a multiyear collaboration, Quest will provide RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular signature response classifier aimed at predicting a patient’s response to TNF inhibitor therapy.

Quest Diagnostics unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.

On this episode I talked to Michael Racke, MD Medical Director of Neurology at Quest Diagnostics. Michael discusses promising advancements in our understanding and treatment of Alzheimer’s disease. He explains how imaging and biomarkers have allowed earlier and more accurate diagnosis, moving from just a clinical picture to actually visualizing amyloid plaques and tau tangles in the brain.

Quest Diagnostics said Thursday that its Haystack Oncology subsidiary has entered a collaboration agreement with Rutgers Cancer Institute of New Jersey for a study of early-stage triple-negative breast cancer patients. Researchers will use Haystack's MRD technology to help evaluate therapeutic response and collect molecular information on individuals undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.

Secaucus-based Quest Diagnostics on Thursday said it was awarded a contract by the Centers for Disease Control and Prevention designed to assess the burden of hepatitis C virus in the U.S. The agreement marks a new phase of a decadelong collaboration between Quest and the CDC to improve hepatitis public health research based on insights from laboratory data.